Thalidomide for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Clinical Trial

BACKGROUND: Coronavirus disease 2019 has become a public health concern with a high number of fatalities. Thalidomide can target inflammatory mediators and decrease inflammation in SARS-CoV-2. MATERIALS AND METHODS: An open-label, randomized controlled trial was conducted on patients with compatible...

Descripción completa

Detalles Bibliográficos
Autores principales: Amra, Babak, Ashrafi, Farzaneh, Torki, Mehdi, Hashemi, Marzieh, Shirzadi, Mohamad, Soltaninejad, Forogh, Sadeghi, Somayeh, Salmasi, Mehrzad, Sami, Ramin, Darakhshandeh, Ali, Nasirian, Maryam, Pourajam, Samaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012021/
https://www.ncbi.nlm.nih.gov/pubmed/36926422
http://dx.doi.org/10.4103/abr.abr_248_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012021/
https://www.ncbi.nlm.nih.gov/pubmed/36926422
http://dx.doi.org/10.4103/abr.abr_248_21

Ejemplares similares